The True Cost of a Backorder Protocol Medicine

We have worked with a wide variety of clients who need fast solutions to their comparator sourcing needs. Many medical studies hit roadblocks when they can’t get materials on time, and that’s where we come in to help.

One client was working on an NIH-sponsored study that was in phase 4. Although they were almost done with the phase 4 trial, they encountered a pressing issue: Bactroban nasal ointment, a protocol medication, was on backorder with no clear delivery date. NIH tried for months to get manufacturers’ assistance with the protocol medication to no avail.

What were their options? They could change the protocol medications and run the phase 4 trial again, which would have cost tens of millions of dollars and a few years delay. Another option would have been to submit the data for the study with the FDA and hope they approved the treatment even though the final cohort didn’t have the protocol medications.

Considering the high level of risk in both those options, it’s a good thing they reached out to GSI instead. We urgently contacted our most reliable distribution partners in search of Bactroban. Each of our partners tapped into their national supply chain and sourced enough Bactroban nasal ointment so NIH could complete the study and submit it for approval. Our solution kept this study on track and avoided lengthy delays for NIH, who know they can come to us next time a similar problem arises.

Contact us today to explore more efficient options for comparator sourcing.

Leave a Reply

Your email address will not be published. Required fields are marked *